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Abstract
Predictors of study retention and scheduled visit attendance in the University of North Carolina Center for AIDS
Research (UNC CFAR) prospective clinical cohort of HIV-infected patients enrolled between 1 January 2001 and
1 January 2008 are reported. At study entry, 1636 participants were 32% female, 58% were African-American,
49% had not received HIV care elsewhere, 71% were receiving or initiated combination antiretroviral therapy,
and 26% were diagnosed with AIDS, with median (quartiles) age of 40 (34; 47) years, distance to clinic of 45 (21;
70) miles, HIV-1 RNA of 1396 (200; 26,750) copies/ml, and CD4 of 374 (182; 602) cells/mm3. Participants
contributed a median of 7 (4; 13) scheduled visits and 2.25 (1.0; 3.9) years alive under follow-up. During 6134
person-years of follow-up, 414 participants dropped out and 145 died. Accounting for differences in death by
participant characteristics, the 6-year cumulative probability of retention was 67% [95% confidence limits (CL):
65, 70%], with 6.75 (95% CL: 6.13, 7.43) drop outs per 100 person-years. In a multivariable Cox proportional
hazards model, retention was higher among participants who were insured, had not received HIV care else-
where, had controlled HIV viremia, and were living in nonurban areas or proximate to the clinic. In a multi-
variable modified Poisson regression model that accounted for differences in drop out and death by participant
characteristics, visit attendance was higher among older, AIDS-diagnosed, immune compromised, and cART-
initiated participants. The UNC CFAR clinical cohort has ample enrollment with retention and visit attendance
modestly influenced by factors such as disease severity.
Introduction
The Center for AIDS Research (CFAR) at the Universityof North Carolina at Chapel Hill (UNC) initiated a pro-
spective clinic cohort study of HIV-infected patients in 2000.
Clinic-based cohorts of HIV-infected patients receiving on-
going medical care in a clinic setting1,2 provide important
information about patients receiving HIV care and have
contributed substantially to understanding HIV and its clin-
ical management.3
Information available from clinic-based cohorts may not be
easily obtained in traditional population-based cohorts. For
example, clinic-based cohorts enroll and follow patients as
they receive HIV care, thereby reflecting actual care provided.
In addition, such cohorts have access to detailed and precise
knowledge of received treatments and clinical outcomes.3
However, clinic-based cohorts rely on data obtained through
the provision of medical care, and hence may be susceptible to
selection bias and confounding based on clinic visit frequency
and retention in care. Understanding HIV care access and
retention in clinic-based cohorts enables development of
strategies for improving HIV care provision and clinical
outcomes.4 Identifying patient characteristics associated
with retention and attendance also informs the conduct of
HIV research by establishing characteristics that should be
considered when correcting for confounding and selection
bias analytically.5 Here, we describe the UNC CFAR HIV
clinical cohort (henceforth, the cohort) and report on predic-
tors of retention and clinic visit attendance.
Materials and Methods
UNC CFAR HIV clinical cohort
Participants. All HIV-infected patients seen at the UNC
HIV clinic who are at least 18 years of age are eligible to enroll
in the cohort if they are able and choose to provide written
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informed consent. Of 2221 HIV-infected patients seen for a
scheduled visit at the UNC HIV clinic between 1 January 2001
and 1 January 2008, 1889 (85%) were asked to participate in
the cohort and 1791 enrolled. The UNC institutional review
board approved all study forms and each enrolled participant
provided written informed consent in English or Spanish.
Data collection. The cohort receives electronic data from
available institutional databases on a daily basis. These data
include all clinically obtained demographic characteristics,
laboratory values, pathology results, and clinic visit infor-
mation. The National Death Index and State of North Carolina
death certificate data are searched semiannually for mortality.
Cause of death is adjudicated based on available information
from the medical record, death certificate, and autopsy re-
ports, if available.
Laboratory measurements and clinical care are provided in
accordance with HIV treatment guidelines6 and as clinically
indicated. At a typical visit, laboratory values at minimum in-
clude a complete blood count with differential, CD4 cell count
and percent, and HIV-1 RNA viral load. Basic chemistry as well
as renal and liver function tests are obtained several times per
year. Lipid levels, syphilis serology, and TB skin testing are
performed yearly in most participants. Viral load was most
commonly measured using standard or ultrasensitive quanti-
tative reverse transcriptase polymerase chain reaction (RT-PCR)
(lower limits of detection of 400 and 50 copies/ml, respectively;
Amplicor HIV Monitor Test; Roche Diagnostic Systems, Inc.,
Branchburg, NJ) and more recently real-time PCR assay (Taq-
Man Assay Roche Diagnostic Systems, Inc., Branchburg, NJ)
with a lower limit of detection of 48 copies/ml.
At cohort enrollment and prospective 6-month intervals
comprehensive and standardized medical record reviews are
completed by trained personnel. These data include medica-
tions including all antiretroviral and prophylactic agents, ill-
nesses including all AIDS-defining clinical conditions,
hospitalizations, and provision of primary HIV care including
vaccinations and routine health maintenance.
All cohort participants are eligible to complete a socio-
demographic, clinical, and behavioral in-person interview.
The data include information on demographics (e.g., educa-
tion, income, employment, housing), clinical history (e.g.,
HIV testing, access to care, antiretroviral therapy adherence,
comorbidities including mental health and substance abuse),
and social and behavioral factors (e.g., social support, quality
of life, sexual behaviors). Additional data from external re-
sources are also incorporated into the cohort including nu-
cleotide sequence data from clinically obtained resistance
testing, data from clinical trial participation, and available
HIV testing data from the State of North Carolina.
Finally, a sample repository of plasma and whole blood cell
pellets is maintained. To date, the repository contains over
25,000 plasma samples and 3000 dry pellet cell specimens.
Plasma samples are collected and stored on each participant at
every visit in which blood is drawn for viral load determi-
nation and cell pellets are collected and stored on each par-
ticipant yearly.
Analysis population
Inclusion criteria. Enrolled participants were considered
to be an active participant in the cohort analysis population on
being seen at a scheduled follow-up clinic visit subsequent to
baseline with laboratory measurements available. Of the 1791
initially enrolled participants 130 did not have a visit subse-
quent to baseline and 25 did not have laboratory measure-
ments available for any time point during study follow-up.
For 98% of the 1636 cohort analysis population participants,
the first scheduled follow-up visit with laboratory measure-
ments available was the scheduled visit subsequent to base-
line. Participants were no longer considered active when they
died or dropped out.
Covariates. Participant characteristics examined in this
analysis include age, distance to the clinic, living in an urban
area, CD4 cell count, HIV RNA level, AIDS status, therapy use,
gender, male homosexual, insurance status (e.g., public, pri-
vate, and none/other), intravenous drug use, and whether the
first HIV care was at UNC. These characteristics were selected
based on clinical knowledge or because they have previ-
ously been shown to predict cohort participation in the clinic
setting.4,7–9 To harmonize all viral load data, values below 400
copies/ml were set to 200 copies/ml. Antiretroviral therapy
(ART) use was defined as any use of an antiretroviral agent for
HIV infection, and combination ART (cART) as the concurrent
use of three or more antiretroviral agents [including triple
nucleoside(tide) reverse transcriptase inhibitor use]. Public
insurance was defined as receiving Medicare or Medicaid.
Outcomes. There were two primary endpoints of interest
in this analysis. The first endpoint was time from study entry
to drop out with administrative censoring by study comple-
tion on 1 January 2008 as well as censoring at date of death.
Participants were considered to have dropped out when they
had not been seen for 18 months. Participants who resumed
care after an 18 or more month hiatus were not reentered into
this analysis.
The second endpoint was attendance at clinic visits. To
evaluate clinic attendance we included only attended sched-
uled clinic visits and excluded walk-in or emergency care
visits. Participants who died or dropped out during follow-up
were censored at their date of death or drop out.
Statistical methods
Percentages for discrete characteristics, or medians and
quartiles for continuous characteristics, are provided for cohort
participants at study entry as well as averaging over the
person-time under follow-up. Study retention was illustrated
for the cohort using a Kaplan–Meier survival curve.10 Given
that the occurrence of death may not be independent of whe-
ther a participant is retained in the study (e.g., sicker partici-
pants more likely to die as well as be retained9) censoring
participants at death may induce selection bias (i.e., informa-
tive censoring) and result in an underestimation of retention
overall and by participant characteristics. Therefore, the re-
tention survival curve was weighted by the inverse probability-
of-censoring due to death to correct for any induced selection
bias associated with measured participant characteristics.11–13
In the resulting weighted population, selection bias associated
with measured characteristics is removed.
To examine possible predictors of drop out in the cohort we
used Cox proportional hazards models.14 Cox models were fit
using the previously described inverse probability-of-
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censoring weights. To determine whether predictors of
retention varied by therapy use or after the first year of cohort
enrollment, we subsequently stratified the Cox model by time
varying initiation of cART and calendar time. The model for
the probability of death used to construct weights included
the following continuous predictors with four-knot restricted
cubic splines with knots placed at the 5, 35, 65, and 95 per-
centiles: time on study, age, distance to the clinic, and CD4 cell
count. Indicators of an AIDS diagnosis, cART initiation, viral
load 400–10,000 copies/ml, viral load >10,000 copies/ml,
gender, private insurance, public insurance, intravenous drug
use, living in an urban area, male homosexual, race, and first
HIV care at UNC were also included in this model. The re-
sultant inverse probability weights had a mean (SD) of 1.00
(0.15) with a range from 0.86 to 4.44. Proportional hazards
were assessed by statistical tests of the product terms between
covariates and time as well as log time.
Scheduled visit attendance was illustrated for the cohort
using a plot of the monthly probability of attending a sched-
uled visit by study follow-up. To examine possible predictors
of visit attendance in the cohort we estimated the risk ratio of
study attendance using a modified Poisson regression15 where
the outcome was an indicator of whether a participant at-
tended a scheduled clinic visit in a given month. We also es-
timated this risk ratio stratifying the Poisson model by cART
use. Given that those most likely to die (or drop out) may be
more (or less) likely to attend scheduled clinic visits,9 censor-
ing participants at death or drop out may be informative and
result in biased estimates of monthly visit probabilities as well
as risk ratios. Therefore, in estimating the probability of and
risk ratios for scheduled visit attendance, we accounted for
informative losses due to censoring participants at drop out or
death by use of inverse probability-of-censoring weights.11,13
The models for the probability of death and drop out used to
construct the weights included the same covariates and
specifications used to model death in the retention analysis.
The resultant inverse probability weights had a mean (SD) of
1.00 (0.18) with a range from 0.68 to 3.98. All analyses were
conducted using SAS (SAS Institute, Cary, NC). Statistical
significance was based on a two-sided type 1 error of 0.05.
Results
In the cohort of 1636 HIV-infected enrolled participants with
at least two attended scheduled visits between 2001 and 2007,
49% (n¼ 802) first received HIV care at UNC. The total amount
of time under HIV care prior to a participant’s baseline visit
was a median (quartiles) of 3.8 (0.6; 7.2) years, including a
median of 1.5 (0.2; 4.9) years under care at UNC prior to
baseline. In Fig. 1 we present a chart depicting the flow of
patients into the study and the disposition of participants as of
1 January 2008. In Fig. 2A we provide an illustration of the
cohort enrollment over calendar years 2001 through 2007.
Enrollment was most rapid in 2001 as the prevalent pool of
FIG. 1. Flow chart of HIV-
infected men and women,
UNC CFAR HIV clinical
cohort, 2001–2007.
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patients was accessed. During 2002 and beyond, approxima-
tely 157 58 patients were enrolled per year.
Characteristics of the participants are provided in Table 1.
At study entry, the cohort was 32% female, 28% nonurban,
58% African-American (AA), 71% cART initiated before or at
study entry, 26% diagnosed with AIDS, with a median
(quartiles) age of 40 (34; 47) years, distance to clinic of 45 (21;
70) miles, viral load of 1396 (200; 26,750), and CD4 count of
374 (182; 602) cells/mm3. The 155 participants excluded from
the analysis population did not differ from the included
participants on most measured characteristics shown in Table
1. However, participants excluded at entry did tend to live
further from the clinic, start their HIV care elsewhere, have a
lower proportion of homosexual men, and be individuals
reporting non-private insurance as compared to included
participants (data not shown).
Participants contributed a median of 7 (4; 13) scheduled
visits and 2.25 (1.0; 3.9) years alive under follow-up between 1
FIG. 2. Enrollment by calendar year (A), probability of study retention by years of study follow-up (B), and probability of a
scheduled clinic visit in a given month by years of study follow-up, among participants remaining in HIV care (C), among the
UNC CFAR HIV clinical cohort, 2001–2007.
Table 1. Characteristics of HIV-Infected Men and Women at Study Entry and over Follow-up,
UNC CFAR HIV Clinical Cohort, 2001–2007
Characteristica Entry N ¼ 1,636 people Follow-up N ¼ 73,609 person-months
Age, years 40 (34; 47) 43 (37; 49)
Female sex, % (n) 32 (521) 32 (23,864)
African-American race, % (n) 58 (956) 59 (43,159)
Intravenous drug use, % (n) 14 (229) 14 (10,252)
Male homosexual, % (n)b 56 (628) 56 (27,761)
Urban area, % (n)c 72 (1,179) 72 (53,060)
Distance to clinic, miles 45 (21; 70) 44 (22; 69)
Insurance, % (n)
Private 28 (460) 32 (23,555)
Publicd 31 (514) 34 (24,720)
None/other 41 (662) 34 (25,334)
First HIV care at UNC, % (n) 49 (802) 51 (37,332)
CD4 count, cells/mm3 374 (182; 602) 439 (259; 656)
CD4 count, % (n)
<200 27 (446) 18 (13,534)
200–350 20 (330) 19 (14,027)
>350 53 (860) 63 (46,048)
Viral load, copies/ml 1,396 (200; 26,750) 200 (200; 6,637)
Viral load, % (n)
<400 40 (653) 59 (43,239)
400–10,000 25 (413) 19 (13,797)
>10,000 35 (570) 22 (16,573)
AIDS, % (n) 26 (428) 32 (23,286)
ART use, % (n) 80 (1,307) 94 (68,972)
cART use, % (n) 71 (1,157) 87 (64,072)
aMedian (quartiles), unless noted otherwise.
bAmong 1,115 men and 49,745 male person-months.
cUrban area defined as >500,000 people in the metropolitan statistical area, compared to less populated areas.
dMedicaid or Medicare.
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January 2001 and 1 January 2008. During 6134 person-years of
follow-up, 414 participants dropped out of the study {6.75 drop
outs per 100 person-years [95% confidence limits (CL): 6.13,
7.43]} and 145 died. Of these 6134 person-years 87% were
contributed while a participant was cART initiated and 32%
occurred while a participant was AIDS diagnosed. The median
(quartiles) age, distance to clinic, viral load, and CD4 count
during follow-up were 43 (37; 49) years, 44 (22; 69) miles, 200
(200; 6,637) copies/ml, and 439 (259; 656) cells/mm3. Of the
1636 participants 1416 (87%) initiated cART before or during
follow-up.
Figure 2B illustrates study retention over nearly 7 years of
follow-up. After accounting for differences in study losses
due to death by measured participant characteristics, the 6-
year retention was 67% (95% CL: 65, 70%). As shown in Fig.
2B, 80% of the cohort was retained for 2.8 years. Table 2
provides hazard ratios for study retention based on the ob-
served data as well as when ratios were adjusted and inverse
probability-of-censoring due to death weighted. Weighted
multivariable-adjusted hazard ratios for study retention in-
dicated higher retention among participants who were pri-
vately or publicly insured, received their first HIV care at
UNC, had controlled HIV-1 viremia, and were living in
nonurban areas or proximate to the clinic. A similar pattern
was observed when the cohort was restricted to cART users
or calendar time after 2002 (data not shown). Initiation
of cART ( p value¼ 0.0215), CD4 cell count >350 cells/mm3
( p value¼ 0.0044), and viral load >10,000 copies/ml
( p value¼ 0.0244) showed evidence of nonproportionality
when assessed by log time.
Figure 2C illustrates the probability of attending a
scheduled clinic visit over nearly 7 years of study follow-up.
After accounting for differences in study losses due to drop
out or death by measured participant characteristics, the
probability of attending a scheduled visit in any given
month was 0.24 (95% CL: 0.24, 0.25) or 2.90 (95% CL: 2.83,
2.97) visits per year. Table 3 provides risk ratios for sched-
uled visit attendance based on the observed data as well as
when ratios were adjusted and inverse probability-of-
censoring due to drop out or death weighted. Weighted
multivariable-adjusted risk ratios for scheduled visit
attendance indicated attendance was higher among partic-
ipants who were older, AIDS diagnosed, immune compro-
mised, and cART initiated. A similar pattern was observed
when the cohort was restricted to cART users (data not
shown).
Discussion
During nearly 7 years of follow-up, the UNC CFAR HIV
clinical cohort has demonstrated ample ability to enroll and
retain participants with only approximately 6.75% of the
participants dropping out per year. This retention estimate is
on par with prospective cohort studies in challenging popu-
lations (e.g., about 10% annual drop out among intravenous
drug users in the AIDS Link to Intravenous Experience
Table 2. Characteristics Associated with Study Retention among 1,636 Participants over 73,609











study retention 95% CLc
Age, per 10 years 1.14 1.03, 1.27 1.12 1.00, 1.25 1.12 1.00, 1.26
Female sex 1.02 0.83, 1.26 1.15 0.89, 1.48 1.15 0.88, 1.48
African-American race 0.99 0.82, 1.21 1.04 0.84, 1.28 1.06 0.86, 1.31
Intravenous drug use 1.00 0.76, 1.32 1.04 0.77, 1.41 1.01 0.75, 1.37
Male homosexuale 1.05 0.86, 1.28 1.21 0.94, 1.55 1.23 0.96, 1.58
Urban areaf 0.83 0.67, 1.04 0.70 0.55, 0.88 0.70 0.55, 0.89
Distance to clinic, per 50 miles 0.79 0.70, 0.89 0.74 0.66, 0.84 0.73 0.65, 0.83
Insurance
Private vs. none/other 1.52 1.20, 1.94 1.46 1.14, 1.86 1.47 1.15, 1.89
Publicg vs. none/other 1.26 1.01, 1.59 1.31 1.03, 1.66 1.31 1.04, 1.67
First HIV care at UNC 1.41 1.16, 1.72 1.49 1.22, 1.83 1.49 1.21, 1.82
CD4 count, cells/mm3
>350 vs. <200 0.98 0.75, 1.27 0.86 0.64, 1.15 0.86 0.64, 1.16
200–350 vs. <200 0.80 0.59 1.09 0.74 0.54, 1.02 0.74 0.54, 1.03
Viral load, copies per ml
>10,000 vs. <400 0.51 0.41, 0.64 0.52 0.40, 0.66 0.52 0.40, 0.67
400–10,000 vs. <400 0.56 0.43, 0.71 0.58 0.45 0.75 0.58 0.45, 0.75
AIDS 1.41 1.13, 1.76 1.30 1.03, 1.64 1.27 1.00, 1.61
cART use 1.39 1.08, 1.80 1.20 0.91, 1.58 1.21 0.92, 1.59
aHazard ratios and confidence limits for study drop out were inverted.
bCL, confidence limits.
cAdjusted for variables present in the table.
dWeighted by the inverse probability-of-censoring due to death.
eCompared to male heterosexuals.
fUrban area defined as >500,000 people in the metropolitan statistical area, compared to less populated areas.
gMedicaid or Medicare.
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study16) as well as other clinic-based cohorts (e.g., 10% annual
drop out among participants in the Centers for AIDS Research
Network of Integrated Clinical Systems17).
Compared to other clinic-based cohorts,17 the UNC clinic
cohort was older at enrollment with a greater proportion of
females and African-Americans. Among participants retained
in the cohort, the majority of the person-time was contributed
while participants were on cART. Scheduled visit attendance
did not appear to be strongly related to any of the examined
participant characteristics. Associations were modest for
those factors that reached statistical significance (e.g., hazard
ratios of 0.93 to 1.14). Therefore, participants who attend
scheduled visits do not appear to be a highly selected subset of
clinic patients.
However, factors that were associated with retention in
the cohort may help predict participant behavior as well as
inform retention strategies and the conduct of HIV research.
The fact that private or public insurance and success on
antiretroviral therapy were associated with retention is not
surprising. The association of nonurban residence, proximal
distance, and receiving first HIV care at UNC with reten-
tion merits further evaluation and may suggest that the
converse groups be targeted by retention efforts. Specific
reasons for loss to follow-up are unknown and demand
further attention. Over one-half of patients at UNC enter a
clinical trial for ART at some point during their care and
may therefore not attend UNC HIV clinic visits during this
interval though laboratory and treatment data are collected
for participants in research studies. Of the 414 participants
who were lost to follow-up, 76 (18%) entered a clinical trial
at some point during their care. Therefore, the number of
participants entering a clinical trial coincident with drop
out is likely low. A proportion of patients is imprisoned
after initiating HIV care at UNC, and although UNC cli-
nicians provide all HIV care in the North Carolina prison
system these patients would be considered lost to follow-up
in these analyses. Moreover it is possible that patients
transfer their HIV care to another provider. Although pos-
sible this is less likely in central-eastern North Carolina
where the number of HIV care providers and clinics is
relatively limited in comparison to urban centers. Finally,
the majority (over 80%) of cohort participants are seen
within 12 months of death, suggesting that many partici-
pants who leave HIV care for 18 or more months eventually
return to reinitiate care.
Higher visit attendance among older and immune com-
promised participants is consistent with observations in the
UAB 1917 clinic cohort. Mugavero and co-authors9 showed
that older participants were less likely to miss one or more
clinic visits during their first year in care. Participants with a
CD4 cell count of 200–350 cells/mm3 were similarly less likely
to miss visits as compared to participants with a CD4 cell
count of 350 cells/mm3. African-Americans as well as par-
ticipants with public rather than private insurance were also
more likely to miss visits. Although possibly due to chance, in
the UNC clinic cohort African-Americans were less likely to
attend clinic visits, whereas those with private or public in-
surance were more likely to attend visits.
Table 3. Characteristics Associated with Scheduled Visit Attendance among 1,636 Participants Remaining











visit attendance 95% CLb
Age, per 10 years 1.07 1.05, 1.09 1.06 1.04, 1.09 1.06 1.04, 1.09
Female sex 0.96 0.92, 1.00 1.02 0.97, 1.08 1.01 0.96, 1.07
African-American race 0.95 0.91, 0.99 0.95 0.91, 0.99 0.96 0.92, 1.00
Intravenous drug use 1.05 0.99, 1.12 1.03 0.97, 1.10 1.03 0.96, 1.11
Male homosexuale 1.04 1.00, 1.08 1.05 1.00, 1.10 1.05 1.00, 1.11
Urban areaf 1.03 0.98, 1.08 1.02 0.97, 1.07 1.02 0.97, 1.07
Distance to clinic, per 50 miles Insurance 0.97 0.94, 1.00 0.97 0.94, 1.00 0.97 0.94, 1.01
Private vs. none/other 1.07 1.02, 1.12 1.04 0.99, 1.09 1.04 0.99, 1.09
Publicg vs. none/other 1.06 1.00, 1.11 1.05 1.00, 1.10 1.05 1.00, 1.11
First HIV care at UNC 1.00 0.96, 1.05 1.03 0.99, 1.07 1.03 0.98, 1.07
CD4 count, cells/mm3
>350 vs. <200 0.90 0.86, 0.95 0.95 0.90 0.99 0.93 0.88, 0.98
200–350 vs. <200 0.97 0.92, 1.03 0.99 0.93, 1.04 0.97 0.92, 1.04
Viral load, copies per ml
>10,000 vs. <400 0.99 0.94, 1.04 1.01 0.96, 1.06 0.99 0.94, 1.04
400–10,000 vs. <400 0.97 0.92, 1.01 1.00 0.96, 1.05 0.99 0.95, 1.04
AIDS 1.17 1.12, 1.22 1.12 1.07, 1.17 1.13 1.08, 1.18
cART use 1.22 1.15, 1.28 1.16 1.10, 1.22 1.14 1.08, 1.20
aRisk ratios and confidence limits conditional on remaining alive and under follow-up.
bCL, confidence limits.
cAdjusted for variables present in the table.
dWeighted by the inverse probability-of-censoring of drop out and death.
eCompared to male heterosexuals.
fUrban area defined as >500,000 people in the metropolitan statistical area, compared to less populated areas.
gMedicaid or Medicare.
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There are limitations to the present work. First, the re-
ported hazard and risk ratios are vulnerable to confounding
by unmeasured factors. Second, the reported hazard and risk
ratios are vulnerable to selection bias due to informative
censoring by unmeasured factors. Third, we do not account
for the fact that variables as assessed are typically imperfect
measures of the true underlying characteristic (e.g., reported
versus actual injection drug use). Fourth, there was evidence
for violation of the proportional hazards assumption on the
log time scale in the retention analysis. Therefore, reported
hazard ratios for the effect of cART initiation, CD4 cell count,
and viral load on retention represent time-weighted aver-
ages of the changing association between these characteris-
tics and retention.
Despite these limitations, included cohort participants did
not appear to substantially differ from those who were ex-
cluded. Use of inverse probability weights to recover the
missed visits for individuals who died or dropped out during
follow-up reduces the potential impact of these missed visits
on study results. Specifically, observed visits are reweighted,
conditional on observed characteristics, to reflect the number
of attended visits that would have occurred in the absence of
deaths or drop outs while respecting the amount of infor-
mation contained in the observed data.13 Informally, a par-
ticipant at a high risk of death or drop out is up-weighted to
account for their peers who died or dropped out. In this study,
there was little difference between the weighted and un-
weighted results. This lack of a difference suggests that the
observed data were not highly selected. Alternatively, the
observed data may be highly selected based on unmeasured
characteristics.
The present results demonstrate that a relatively large and
well-defined clinical cohort in the epicenter of the U.S. epi-
demic, the southeast, has adequate retention with limited
selection bias apparent in the observed population over
nearly 7 years of follow-up. In conclusion, the UNC CFAR
HIV clinical cohort is a viable national resource for the con-
duct of HIV-related biomedical research.
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